Merck KGaA Profit Beats Estimates on Cost-Cutting

Merck KGaA Profit Beats Estimates on Cost-Cutting Play

May 14 (Bloomberg) -- Merck KGaA, the German maker of cancer drug Erbitux, said first-quarter profit rose on higher-than-expected savings from a reorganization program, and forecast it will achieve 2014 targets a year ahead of schedule. Mark Barton reports on Bloomberg Television's "Countdown." (Source: Bloomberg)

blog comments powered by Disqus